BlackRock Health Sciences Trust II
BMEZ
New York Stock Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xiang Liu
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 55 East 52nd Street New York City NY United States of America 10055
- IPO Date
- Jan 29, 2020
- CIK
- 0001785971
- Website
- blackrock.com
- Similar Companies
- Business
- BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment trust that seeks total return and income through a combination of current income, current gains, and long-term capital appreciation, primarily by investing at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to such industries; the portfolio emphasizes mid- and small-capitalization healthcare companies across subsectors including biotechnology, pharmaceuticals, life sciences tools and services, medical devices and supplies, health care providers and services, health care technology, and health care equipment and distributors, supplemented by a tactical single-stock covered call option-writing strategy to generate premiums and manage risk, as well as meaningful allocations to private investments in innovative healthcare firms such as ADARx Pharmaceuticals, PsiQuantum, Insmed, and Alnylam Pharmaceuticals. The Trust, advised by BlackRock Advisors, LLC, was incorporated in 2019, launched in March 2020 with an initial public offering price of $20 per share, and is headquartered at 100 Bellevue Parkway, Wilmington, Delaware, United States; it operates globally with primary exposure to U.S.-based companies (approximately 81%) alongside investments in firms located in Switzerland, China, the United Kingdom, Germany, Denmark, Japan, Israel, and Belgium, targeting institutional and retail investors seeking healthcare sector growth and income. As of mid-2025, the portfolio includes top holdings such as Alnylam Pharmaceuticals (biotechnology), Veeva Systems (health care technology), Insmed (biotechnology), PsiQuantum (semiconductors with healthcare applications), and West Pharmaceutical Services (life sciences tools), with private investments comprising about 13.4% of net asset value across 19 companies focused on next-generation therapies in neuroscience, immunology, oncology, and diagnostics. In recent major developments, the Trust completed a tender offer in April 2025 for up to 40% of its outstanding shares at 99.5% of net asset value to provide shareholder liquidity; on September 10, 2025, its Board approved a shift from a floating-rate to a level-rate managed distribution plan effective with the October 2025 distribution at $0.1100 per share monthly, aiming to enhance stability while supporting net asset value growth amid distributions estimated at 100% return of capital through mid-2025; portfolio adjustments in Q2 2025 included increased exposure to health care services, distributors, and equipment with regulatory tailwinds (e.g., continuous glucose monitoring), reduced biotechnology weighting, and gains from private holding ADARx Pharmaceuticals' partnership with AbbVie announced in the quarter, which provided $335 million upfront plus milestones for next-generation therapies. The Trust maintains a contingent limited term structure with a planned dissolution or Eligible Tender Offer for 100% of shares at net asset value around January 29, 2032 (extendable up to 18 months), requiring at least $200 million in net assets post-tender to potentially convert to perpetual existence, and its name was updated to BlackRock Health Sciences Term Trust in April 2023 to highlight this feature.